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OBJECTIVES We sought to compare the maternal and fetal outcomes of patients with severe mitral stenosis
submitted to percutaneous balloon dilation versus open mitral valve commissurotomy (MVC)
during pregnancy.
BACKGROUND Heart failure in patients with mitral stenosis complicating pregnancy is a common problem
in developing countries. Since 1984, percutaneous dilation of the mitral valve using a balloon
catheter has become a therapeutic alternative to open heart surgery. Although the efficacy of
percutaneous mitral valve balloon dilation is well established, its results have never before been
compared with the results of commissurotomy during pregnancy.
METHODS We compared the clinical and obstetric complications in 45 women who were treated with
percutaneous mitral valve balloon dilation (group I, n 5 21; from 1990 to 1995) or open
MVC (group II, n 5 24; from 1985 to 1990) for severe heart failure due to mitral stenosis
during pregnancy.
RESULTS In our study, percutaneous balloon dilation of the mitral valve had a success rate of 95%
(Gorlin formula) and 90.5% (echocardiographic “pressure half-time” method), as demon-
strated by the final mitral valve area achieved. This improvement was followed by a marked
decrease in the mitral valve gradient, left atrial pressure and mean pulmonary artery pressure.
Patients in both groups had similar improvements in symptoms. Patients who underwent
percutaneous balloon dilation had significantly fewer fetal complications, with a reduction in
fetal and neonatal mortality (1 death in group I vs. 8 in group II, p 5 0.025).
CONCLUSIONS Percutaneous balloon mitral valvuloplasty is safe and effective and appears to be preferable for
the fetus, compared with open MVC during pregnancy. (J Am Coll Cardiol 2001;37:900–3)
© 2001 by the American College of Cardiology
The safety and efficacy of percutaneous balloon mitral
valvuloplasty (PBMV) has been reported by several investi-
gators (1,2). In patients with mitral stenosis and a pliable
valve anatomy, PBMV has been shown to be equivalent to
either closed or open mitral valve commissurotomy (MVC)
(3–5).
Patients with mitral stenosis complicating pregnancy
represent a common health problem in the developing
world (6). These women frequently present with worsening
symptoms, often necessitating prolonged periods of bed rest
and hospitalization, despite optimization of clinical treat-
ment (7).
Before the introduction of PBMV in 1984 (1), MVC was
the only treatment available for patients with refractory
symptoms of heart failure. Although performing this pro-
cedure during pregnancy does not add risk for the mother,
the fetal risk is increased (fetal mortality 6% to 33%) (8–10).
This increase in fetal mortality may be due to either the
effects of general anesthesia, thoracotomy or extracorporeal
circulation. In contrast, PBMV during pregnancy has been
reported without fetal loss and may be the preferred
modality of treatment in this subset of patients (11–15).
However, no study has shown the superiority of PMBV
over open MVC during pregnancy.
METHODS
From January 1985 to August 1995, a total of 45 consecu-
tive pregnant women underwent MVC in our institution for
control of symptoms of mitral stenosis. All patients were in
New York Heart Association functional class III or IV
despite hospital admission and intensive medical therapy.
Twenty-one patients were submitted to balloon mitral
valvuloplasty (group I) and 24 were submitted to MVC
(group II). The first 24 patients (from 1985 to 1990)
underwent open MVC, and the following 21 patients (from
1990 to 1995) underwent a percutaneous procedure.
All patients who had MVC or PMBV between 1985 and
1995 were included. Patients in functional class III or IV
heart failure were admitted and treated with an intravenous
diuretic agent, digitalis or, occasionally, beta-blockers.
Two-dimensional echocardiograms were obtained in all
patients treated by balloon valvuloplasty, whereas M-mode
echocardiograms were used for the analysis of the mitral
valve anatomy in the surgical group, because two-
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dimensional echocardiography was not available at our
institution before 1990.
Clinical indications. The indication for valvuloplasty in-
cluded severe heart failure despite intensive medical treat-
ment. All patients presented with severe orthopnea or
pulmonary edema despite treatment with a high dose of
diuretic agents (furosemide, 80 mg to 240 mg/day). Patients
treated medically who returned to functional class II were
excluded. In most cases, the interventions were done on an
urgent basis because of clinical deterioration. In the surgical
group, visual inspection of the mitral valve apparatus was
used for deciding between mitral valve replacement or
commissurotomy. Mitral valve commissurotomy was per-
formed in cases of predominant commissural fusion, little or
no calcification and absence of major deformities of the
mitral valve. Eight patients submitted to mitral valve re-
placement were not analyzed in this study. Of these, five
had mitral stenosis as a predominant lesion, but the mitral
valve apparatus was not suitable for commissurotomy (either
PBMV or mitral valve surgery) because of severe deformity,
with a Block echocardiographic score .11; and three had
significant concomitant mitral regurgitation.
Patients were submitted to balloon valvuloplasty when
the two-dimensional echocardiogram revealed severe mitral
stenosis with minimal or absent mitral regurgitation, a
mitral valve score ,10 and the absence of detected atrial
thrombus (16).
All patients were followed after the procedure, as well as
during the gestational period, puerperium and delivery.
Procedure. Mitral valve commissurotomy was performed
under general anesthesia and extracorporeal circulation with
continuous flow. Mild hypothermia (32°C), partial hemodi-
lution and blood cardioplegia in the aortic root were used.
High flow and high pressure cardiopulmonary bypass were
used and adjusted according to fetal heart rate monitoring.
Heparin was given to maintain an activated coagulation
time between 250 and 300 s. The surgical procedure was
undertaken with the patient lying supine with the lower part
of the body tilted to the left, with the use of a cushion, to
minimize inferior vena cava compression by the uterus.
After visual inspection, the commissures were incised.
Fused chordae separation and splitting of the underlying
papillary muscle were done as needed. The technique used
by our surgeons was very similar to that reported by other
surgeons in recent reviews of cardiac surgery during preg-
nancy (10).
Percutaneous balloon mitral valvuloplasty was performed
in the catheterization laboratory, and a plumb abdominal
and pelvic shield was used. All of the procedures were done
under local anesthesia by a transseptal, anterograde tech-
nique, as described by Inoue et al. (1). Three vascular
accesses were obtained: the right jugular vein for the
introduction of a Swan-Ganz catheter, the left femoral
artery for the introduction of a pigtail catheter and the right
femoral vein for the dilation catheter. Hemodynamic vari-
ables, including the Gorlin valve area, were obtained before
and after each balloon inflation. To minimize radiation
exposure, contrast ventriculograms were not performed.
Transthoracic echocardiography and Doppler echocardiog-
raphy were performed 48 h after the procedure to assess the
mitral valve area and the presence and magnitude of mitral
insufficiency. The dilation was considered successful if the
mitral valve area increased to .1.5 cm2, without significant
mitral insufficiency. An increase in the mitral valve area of
25%, with a final area ,1.5 cm2 was considered a partial
success.
Data from the patients in the surgical group were
obtained by a review of medical records, whereas the data
from patients in the balloon dilation group were collected
prospectively.
Statistical analysis. The Student t test was used for the
comparison of continuous variables between group I
(PBMV) and group II (MVC) and between pre- and
postvalvuloplasty in each group. The Fischer exact test was
utilized for comparison of the demographic data between
the two groups. A value p , 0.05 was selected as the level
of statistical significance.
RESULTS
As shown in Table 1, both groups were comparable in terms
of demographic data. The patients in both groups were
young, in the second trimester of pregnancy and highly
symptomatic. Atrial fibrillation was rare. Heart rates were
relatively low in both groups, and these were measured in
Abbreviations and Acronyms
MVC 5 mitral valve commissurotomy
PBMV 5 percutaneous balloon mitral valvuloplasty
Table 1. Data of Patients Submitted to Mitral Balloon
Valvuloplasty and Mitral Valve Commissurotomy
PBMV
(n 5 21)
MVC
(n 5 24)
p
Value
Age (yrs) 24.6 6 4.8 27.4 6 5.2 0.06
Gestational age (weeks) 25.2 6 7.2 22.6 6 6.6 0.23
NYHA functional class (n)
III 17 20 1.0
IV 4 4 1.0
Heart rate (beats/min) 78.4 6 8.7 74.7 6 10.0 0.20
Atrial fibrillation (n) 0 1 1.0
Medical therapy before
procedure (n)
Diuretics 21 24 1.0
Digoxin 18 20 1.0
Beta-blocker 7 6 0.74
Medical therapy after
procedure (n)
Diuretics 17 20 0.85
Digoxin 18 20 1.0
Beta-blocker 3 4 0.83
Data are presented as the mean value 6 SD or number of patients.
MVC 5 mitral valve commissurotomy; NYHA 5 New York Heart Association;
PBMV 5 percutaneous balloon mitral valvuloplasty.
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the surgical group just before the operation from data
obtained from nurses’ notes. In all cases, the heart rates
represent the status of the patient after prolonged bed rest
and diuretic therapy.
Percutaneous balloon mitral valvuloplasty was successful
in 95% of patients, as evaluated by the Gorlin formula in the
catheterization laboratory, and in 90.5%, as evaluated by the
pressure half-time method 48 h after the procedure. Two
patients had partial success in that their mitral valve area did
not increase to .1.5 cm2. Pre- and post-PBMV hemody-
namic data for these patients are shown in Table 2.
In the group treated with PBMV, “de novo” mild mitral
regurgitation developed in four patients. One patient with
mild MR before the procedure developed moderate insuf-
ficiency. There were no severe complications, including
cardiac perforation, tamponade or embolization.
There was only one death in the entire group of patients,
and that was in the surgical group. There was a significant
improvement of symptoms in all except one patient in the
surgical group, in whom heart failure persisted until the end
of pregnancy. All other patients were in functional class I or
II at the end of pregnancy and puerperium. There was no
statistically significant difference in functional class in
follow-up after the procedure when the groups were com-
pared.
Fetal and neonatal complications. In group I (PBMV),
there was only one neonatal death in a premature child with
an esophageal malformation. No fetal death occurred in
group I. In contrast, there were six fetal and two neonatal
deaths in group II (surgical group). The difference in the
combined occurrence of fetal and neonatal deaths was
significant when the groups were compared (1 vs. 8,
respectively; p 5 0.025) (Table 3). Fetal deaths occurring up
to 24 h after the operation and PBMV were 0 and 5,
respectively (p 5 0.051). In the five patients operated on
after 1990 for mitral stenosis without a pliable valve, a
porcine mitral valve prosthesis was used, and there were
three fetal losses. In the three patients who were submitted
to mitral valve replacement for mitral regurgitation, there
was one fetal loss.
DISCUSSION
Mitral stenosis is highly prevalent in developing countries.
In Brazil, rheumatic heart disease is responsible for 50% of
the cardiac complications during pregnancy, and mitral
stenosis is the most important lesion in 75% of these
patients (17). Most of these women have worsening of their
symptoms, reaching functional class III or IV by the second
or third trimester of pregnancy. Clinical management is
often difficult and requires prolonged periods in the hospi-
tal.
In cases of uncontrolled heart failure, MVC was the only
treatment option before the advent of PBMV. Although
this surgery carries a low risk for the mother, it carries a
substantial risk of fetal mortality (10,18,19), especially when
open MVC is performed. In our institution, closed MVC
was abandoned because of the better functional results of
open MVC under extracorporeal circulation and direct valve
visualization.
Several reports have reported the favorable results of
PBMV performed during pregnancy, with immediate he-
modynamic success and clinical benefit, consequent to the
increase of mitral valve area (11–15). The hazards of X-ray
exposure can be minimized by avoiding the procedure
during the first half of pregnancy (period of organogenesis)
and by appropriate shielding of the mother’s abdominal and
pelvic regions (15). We compared both modalities of treat-
ment in a selected group (pregnant women with severe
mitral stenosis and mitral valve anatomy suitable for com-
missurotomy, either percutaneously or by operation). The
demographic data of both groups were very similar, and the
indications for the procedure remained unchanged during
the entire study period.
This study shows that PBMV appears to be a better
alternative than surgical repair owing to a significant reduc-
tion in fetal and neonatal mortality. To provide more solid
evidence, a definitive conclusion based on a randomized trial
is desired, but a study such as this is not feasible. Thus, we
believe that PBMV should be considered the treatment of
choice for severe mitral stenosis complicating the course of
pregnancy in patients with a favorable valve anatomy.
Study limitations. This study has several limitations inher-
ent to the retrospective analysis of the surgical group. Also,
the two groups were compared in different intervals, during
which improvements in patient care could have favored the
outcome of the group treated by PBMV. However, the two
groups were similar clinically at the time of their procedures;
the indication for the interventions remained unchanged,
Table 2. Hemodynamic Data of Patients Before and After
Percutaneous Balloon Mitral Valvuloplasty
Before
PBMV
After
PBMV
p
Value
Left atrial pressure (mm Hg) 21.4 6 8.9 9.5 6 3.4 ,0.0001
Right atrial pressure (mm Hg) 12.0 6 2.8 10.2 6 3.1 0.06
Transmitral valvar gradient
(mm Hg)
15.9 6 8.6 4.7 6 3.3 ,0.0001
Mean pulmonary artery pressure
(mm Hg)
38.2 6 15.6 21.2 6 8.3 ,0.0001
Cardiac index (liters/m per m2) 3.1 6 0.5 3.4 6 0.5 0.03
Mitral valve area by Gorlin
formula (cm2)
1.04 6 0.25 2.16 6 0.37 ,0.0001
Mitral valve area by
echocardiography (cm2)
0.96 6 0.15 1.84 6 0.30 ,0.0001
Data are presented as the mean value 6 SD.
PBMV 5 percutaneous balloon mitral valvuloplasty.
Table 3. Neonatal and Fetal Mortality
Mortality PBMV n (%) MVC n (%)
Yes 1 (4.8%) 8 (37.9%)*
No 20 (95.2%) 16 (62.1%)
Total 21 (100%) 24 (100%)
*p 5 0.025 by the Fisher exact test.
Abbreviations as in Table 1.
902 Souza et al. JACC Vol. 37, No. 3, 2001
Mitral Balloon Dilation vs. Commissurotomy in Pregnancy March 1, 2001:900–3
and there were no major surgical or clinical advancements
that, in our view, could have resulted in better fetal
protection if MVC had been performed earlier.
There were also differences in the preoperative evaluation
of patients between the two groups. Patients treated surgi-
cally were evaluated preoperatively by M-mode echocardi-
ography. A detailed two-dimensional echocardiogram of the
heart is mandatory in the proper evaluation of PBMV, but
not for open mitral valve surgery. Furthermore, two-
dimensional echocardiography was not available before
1990 at our hospital. In addition, a hemodynamic assess-
ment was not done preoperatively in the surgical group
because of pregnancy.
Finally, beta-blockers were infrequently used, and their
use in small doses could have, theoretically, improved the
patients’ clinical status. However, the use of high doses of
beta-blockers may not be safe, as it can increase the risk of
abortion and premature birth (20).
Conclusions. This study strongly supports the role of
PBMV as the treatment of choice for refractory congestive
heart failure in pregnant women with mitral stenosis and a
favorable mitral valve anatomy.
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